§ 356b. Reports of postmarketing studies
1,010 words·~5 min read·
/usc/title-21/section-356bA research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)Submission
(1)In general A sponsor of a drug that has entered into an agreement with the Secretary to conduct a postmarketing study of a drug shall submit to the Secretary, within 1 year after the approval of such drug and annually thereafter until the study is completed or terminated, a report of the progress of the study or the reasons for the failure of the sponsor to conduct the study. The report shall be submitted in such form as is prescribed by the Secretary in regulations issued by the Secretary.
(2)Accelerated approval Notwithstanding paragraph (1), a sponsor of a drug approved pursuant to accelerated approval shall submit to the Secretary a report of the progress of any study required under section 356(c) of this title, including progress toward enrollment targets, milestones, and other information as required by the Secretary, not later than 180 days after the approval of such drug and not less frequently than every 180 days thereafter, until the study is completed or terminated. The Secretary shall promptly publish on the website of the Food and Drug Administration, in an easily searchable format, the information reported under this paragraph.
(3)Agreements prior to effective date Any agreement entered into between the Secretary and a sponsor of a drug, prior to November 21, 1997, to conduct a postmarketing study of a drug shall be subject to the requirements of paragraph (1). An initial report for such an agreement shall be submitted within 6 months after the date of the issuance of the regulations under paragraph (1).
(b)Consideration of information as public information Any information pertaining to a report described in subsection
(a)shall be considered to be public information to the extent that the information is necessary—
(1)to identify the sponsor; and
(2)to establish the status of a study described in subsection
(a)and the reasons, if any, for any failure to carry out the study.
(c)Status of studies and reports The Secretary shall annually develop and publish in the Federal Register a report that provides information on the status of the postmarketing studies—
(1)that sponsors have entered into agreements to conduct; and
(2)for which reports have been submitted under subsection (a)(1).
(d)Disclosure If a sponsor fails to complete an agreed upon study required by this section by its original or otherwise negotiated deadline, the Secretary shall publish a statement on the Internet site of the Food and Drug Administration stating that the study was not completed and, if the reasons for such failure to complete the study were not satisfactory to the Secretary, a statement that such reasons were not satisfactory to the Secretary.
(e)Notification With respect to studies of the type required under section 356(c)(2)(A) of this title or under section 314.510 or 601.41 of title 21, Code of Federal Regulations, as each of such sections was in effect on the day before the effective date of this subsection, the Secretary may require that a sponsor who, for reasons not satisfactory to the Secretary, fails to complete by its deadline a study under any of such sections of such type for a drug or biological product (including such a study conducted after such effective date) notify practitioners who prescribe such drug or biological product of the failure to complete such study and the questions of clinical benefit, and, where appropriate, questions of safety, that remain unanswered as a result of the failure to complete such study. Nothing in this subsection shall be construed as altering the requirements of the types of studies required under section 356(c)(2)(A) of this title or under section 314.510 or 601.41 of title 21, Code of Federal Regulations, as so in effect, or as prohibiting the Secretary from modifying such sections of title 21 of such Code to provide for studies in addition to those of such type.
(June 25, 1938, ch. 675, § 506B, as added Pub. L. 105–115, title I, § 130(a), Nov. 21, 1997, 111 Stat. 2331; amended Pub. L. 107–188, title V, § 506, June 12, 2002, 116 Stat. 693; Pub. L. 112–144, title IX, § 902(c), July 9, 2012, 126 Stat. 1088; Pub. L. 117–328, div. FF, title III, § 3210(b), Dec. 29, 2022, 136 Stat. 5823.)
Connections65 cite this · traces to 4
Cited by 65 sections · top 60
public-private-law
U.S. Code
register
- NoticesNotice
- NoticesNotice
- NoticesNotice
- Rules and RegulationsNotice
- NoticesNotice
- NoticesNotice
- NoticesNotice of availability
- NoticesNotice of availability
- Proposed RulesNotice
- Rules and RegulationsNotice of availability
- Proposed RulesTemporary rule; modification of a closure
- NoticesAdvance Notice of Intent to Prepare an Environmental Impact Statement
- NoticesNotice of availability
- NoticesFinal rule
- NoticesNotice
- NoticesNotice
- NoticesNotice of availability
- NoticesNotice of availability
- NoticesNotice of availability
- NoticesNotice of availability
- NoticesNotice of availability
- NoticesNotice
- NoticesNotice of availability
- NoticesNotice of availability
- NoticesNotice of availability
- NoticesNotice of availability
- NoticesNotice of availability
- NoticesNotice of availability
- NoticesNotice
- Rules and RegulationsNotice
- NoticesNotice
- NoticesNotice of availability
- NoticesNotice
- NoticesNotice of availability
- NoticesNotice of availability
- NoticesFinal rule
- NoticesNotice
- Proposed RulesNotice of availability
- Proposed RulesNotice of availability
- NoticesNotice
- NoticesNotice of a new system of records (SOR)
- NoticesNotice
statutes-at-large
- Public Law 112–144To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes
- Public Law 117–328Making consolidated appropriations for the fiscal year ending September 30, 2023, and for providing emergency assistance for the situation in Ukraine, and for other purposes
- Public Law 107–188To improve the ability of the United States to prevent, prepare for, and respond to bioterrorism and other public health emergencies
- Public Law 105–115To amend the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to improve the regulation of food, drugs, devices, and biological products, and for other purposes
statute-compilations
bill
- Sec. 3210Modernizing accelerated approval
- Sec. 3210Modernizing accelerated approval
- Sec. 2Postapproval studies required for accelerated approval drugs
- Sec. 804Postapproval studies and program integrity for accelerated approval drugs
- Sec. 804Postapproval studies and program integrity for accelerated approval drugs
- Sec. 804Postapproval studies and program integrity for accelerated approval drugs
- Sec. 804Postapproval studies and program integrity for accelerated approval drugs
- Sec. 506Modernizing accelerated approval
14 references not yet in our index
- June 25, 1938, ch. 675, § 506B
- Pub. L. 105–115, title I, § 130(a)
- 111 Stat. 2331
- Pub. L. 107–188, title V, § 506
- 116 Stat. 693
- Pub. L. 112–144, title IX, § 902(c)
- 126 Stat. 1088
- 136 Stat. 5823
- Pub. L. 112–144
- Pub. L. 107–188
- Pub. L. 107–188, title V, § 508
- 116 Stat. 694
- section 501 of Pub. L. 105–115
- Pub. L. 105–115, title I, § 130(b)
Citation graph
cites case law
§ 356b
Reports of postmarketing studies
Fed. Reg.×43
Bills×10
Stat.×6
U.S.C.×4
Pub. L.×1
Stat. Comp.×1
ActJune 25, 1938, ch. 675, § 506B
Pub. L.Pub. L. 105–115, title I, § 130(a)
Stat.111 Stat. 2331
Pub. L.Pub. L. 107–188, title V, § 506
Stat.116 Stat. 693
Cites 18 · showing 9Cited by 65 across 6 sources